ArticleTherapeutic advances in medical oncology2022

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.

Sara Elena Rebuzzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.